A circulating biomarker risk-prediction model correlates with CHADS-2 risk score in chronic atrial fibrillation

IJC Metabolic and Endocrine

Volumn 6, Issue , 2015, Pages 24-26

  Negi, Smita I ^a   Greener, Ian ^b,d   Anand, Aashish ^c   Dudley, Samuel C ^b,d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Lifespan   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Biomarkers; CHADS 2 score; Inflammation; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHADS 2 SCORE; CLINICAL ASSESSMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RISK ASSESSMENT; SMOKING;

EID: 84961289131     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.01.002     Document Type: Article

References (27)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2014, 129:399-410.
2. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
3. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., et al. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010, 12:1360-1420.
4. Fang M.C., Go A.S., Chang Y., Borowsky L.H., Pomernacki N.K., Udaltsova N., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58:395-401.
5. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
6. Wang T.J., Massaro J.M., Levy D., Vasan R.S., Wolf P.A., D'Agostino R.B., et al. A risk scores for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003, 290:1049-1056.
7. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
8. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., et al. C reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
9. Conway D.S., Buggins P., Hughes E., Lip G.Y. Predictive values of indices of inflammation and hypercoaguability on success of cardioversion in persistent atrial fibrillation. Am J Cardiol 2004, 94:508-510.
10. Neuman R.B., Bloom H.L., Shukrullah I., Darrow L.A., Kleinbaum D., Jones D.P., et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007, 53:1652-1657.
11. Dudley S.C., Hoch N.E., McCann L.A., Honeycutt C., Diamandopoulos L., Fukai T., et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005, 112:1266-1273.
12. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002, 106:2854-2858.
13. Cornelli U., Terranova R., Luca S., Cornelli M., Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the DROM tests as a marker of oxidative stress. J Nutr. 2001, 131:3208-3211.
14. Roberts L.J., Milne G.L. Isoprostanes. J Lipid Res 2009, 50:S219-S223.
15. Crandall M.A., Horne B.D., Day J.D., Anderson J.L., Muhlestein J.B., Crandall B.G., et al. Atrial fibrillation and CHADS-2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol 2009, 32:648-652.
16. Marott S.C., Nordestgaard B.G., Zacho J., Friberg J., Jensen G.B., Tybjaerg-Hansen A., et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010, 56:789-795.
17. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.
18. Lip G.Y., Patel J.V., Hughes E., Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with non valvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007, 38:1229-1237.
19. Roldán V., Marín F., Díaz J., Gallego P., Jover E., Romera M., et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012, 10:1500-1507.
20. Hermida J., Lopez F.L., Montes R., Matsushita K., Astor B.C., Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2012, 109:95-99.
21. Conway D.S., Buggins P., Hughes E., Lip G.Y. Relationship of interleukin-6 and C reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004, 43:2075-2082.
22. Negi S., Sovari A.A., Dudley S.C. Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 2010, 10:262-268.
23. Jeong E.M., Liu M., Sturdy M., Gao G., Varghese S.T., Sovari A.A., et al. Metabolic stress, reactive oxygen species, and arrhythmia. J Mol Cell Cardiol 2012, 52:454-463.
24. Korantzopoulos P., Kolettis T.M., Galaris D., Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007, 115:135-143.
25. Guazzi M., Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart 2009, 95:102-106.
26. Kim Y.M., Kattach H., Ratnatunga C., Pillai R., Channon K.M., Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008, 51:68-74.
27. Jaulmes A., Sansilvestri-Morel P., Rolland-Valognes G., Bernhardt F., Gaertner R., Lockhart B.P., et al. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb Res 2009, 124:439-446.